Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for pharmaceutical industry professionals · Sunday, July 13, 2025 · 830,527,707 Articles · 3+ Million Readers

FDA Public Workshop: Future Needs for the Development of Interchangeable Products - 09/19/2025


Date:
September 19, 2025
Time:
9:00 a.m. - 1:00 p.m. ET


Under the Biosimilar User Fee Act (BsUFA) reauthorization commitment letter for fiscal years 2023 to 2027 (BsUFA III), FDA will hold a scientific workshop on the development of interchangeable products to help identify future needs (e.g., guidance, research) on or before October 31, 2025. The U.S. Food and Drug Administration (FDA) is hosting a hybrid in-person/virtual public workshop on September 19, 2025, to meet the BsUFA III commitment. The meeting agenda includes presentations by representatives from the biosimilar industry on the future needs for the development of interchangeable products, discussions on specific interchangeable topics, and a panel discussion with industry.

Within 12 months following the public workshop, FDA will issue a draft strategy document for public comment that outlines the specific actions the agency will take to facilitate the development of interchangeable biosimilar biological products. FDA will consider public input and will publish a final strategy document within 9 months after the close of the public comment period on the draft strategy document.

The meeting agenda, federal register notice, additional materials, and any other updates will also be posted to this website as they become available.

Registration: https://www.eventbrite.com/e/future-needs-for-the-development-of-interchangeable-products-tickets-1481835763659

Powered by EIN Presswire

Distribution channels: Healthcare & Pharmaceuticals Industry

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release